InfaCare 64,185-205

Overview

Status: Not yet recruiting
Keywords: Stannsoporfin , Pediatrics , Hyperbilirubinemia
IRB Number: 00066249
Specialty: Pediatrics, General
Sub Specialties:

Brief Summary

The objectives of this follow up study are to evaluate the long-term effects of stannsoporfin (Stanate) on the health, growth, and development of patients who received a single dose of stannsoporfin with PT used to treat hyperbilirubinemia compared with patients in the control (placebo plus PT) group in clinical trial 64,185-204.

Principal Investigator: Julie Shakib
Department: Pediatric Administration
Co Investigator: Michael Spigarelli

Contact Information

Name:Priscilla Cowan
Phone: 801-213-3401
Email: priscilla.rosen@hsc.utah.edu

Inclusion Criteria

Patients will meet the following entry criteria for study eligibility:

• Patients who have received IMP (stannsoporfin or placebo) in clinical trial 64,185-204

• Written informed consent provided by parents/guardians

Exclusion Criteria

none